2,4,6-Trihydroxy-3-nitrobenzamide | 136850-51-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2,4,6-Trihydroxy-3-nitrobenzamide
• CAS: 136850-51-6
• 化学式: C7H6N2O6
• 分子量: 214.13
• InChiKey: CEHJYEXLKQVWOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  150
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] D-ALANINE PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-METHYL 2'-FLUORO GUANOSINE NUCLEOSIDE COMPOUNDS FOR THE TREATMENT OF HCV<br/>[FR] PRONUCLÉOTIDES PHOSPHORAMIDATES DE D-ALANINE DE COMPOSÉS DE NUCLÉOSIDE 2'-MÉTHYL 2'-FLUORO GUANOSINE DANS LE TRAITEMENT DU VHC
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2015066370A1

  公开（公告）日：2015-05-07

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof; where W and R are as described herein.

  本文提供了用于治疗黄病毒科感染，包括HCV感染的化合物、组合物和方法。在某些实施例中，披露了核苷衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合给药。在某些实施例中，这些化合物是D-丙氨酸磷酰胺前核苷酸的2'-甲基2'-氟鸟苷核苷衍生物，对于例如人体中的HCV感染的治疗显示出显著的疗效和生物利用度。在某些实施例中，这些化合物是Formula I或其药用可接受的盐、溶剂合物、立体异构体形式、互变异构体形式或多形形式；其中W和R如本文所述。
• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2015042375A1

  公开（公告）日：2015-03-26

  Provided herein are hepatitis C virus inhibitor compounds, for example, of any of Formulae I to XIV, Ilia to XlVa, Illb to XlVb, IIIc to XIVc, Hid to XlVd, Ille to XlVe, IA to IAe, IIA to IIAe, IB, IIB to IIBd, IIIB to IIIBd, IC to ICc, ID to IDd, and IE to lEc.pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for treating an HCV infection.

  本文提供了乙型肝炎病毒抑制剂化合物，例如任何I至XIV式，Ilia至XlVa，Illb至XlVb，IIIc至XIVc，Hid至XlVd，Ille至XlVe，IA至IAe，IIA至IIAe，IB，IIB至IIBd，IIIB至IIIBd，IC至ICc，ID至IDd，以及IE至IEc的化合物。还包括包含这些化合物的药物组合物，以及其制备方法。还提供了用于治疗HCV感染的方法。
• Dosing regimen for gemcitabine HCV therapy
  申请人：——

  公开号：US20030225029A1

  公开（公告）日：2003-12-04

  A dosage regiment for the treatment of a Flaviviridae infection, including a hepatitis C viral infection, that includes administering gemcitabine (or its salt, prodrug or derivative, as described herein) in a dosage range of approximately 50 mg/m 2 to about 1300 mg/m 2 per day for between one and seven days (e.g. 1, 2, 3, 4, 5, 6, or 7 days) followed by cessation of therapy. Viral load is optionally monitored over time, and after cessation, viral rebound is monitored. Therapy is not resumed unless a significant viral load is again observed, and then therapy for 1-7 days and more preferred, 1, 2 or 3 days, is repeated. This therapy can be continued indefinitely to monitor and maintain the health of the patient.

  一种用于治疗黄病毒科感染的剂量方案，包括丙型肝炎病毒感染，在一到七天内每天给予吉西他滨（或其盐、前药或衍生物，如本文所述）的剂量范围约为50毫克/平方米至约1300毫克/平方米，随后停止治疗。可选择随时间监测病毒载量，并在停止治疗后监测病毒反弹。除非再次观察到显著的病毒载量，否则不会恢复治疗，然后重复1-7天的治疗，更倾向于1、2或3天。这种疗法可以无限期地继续以监测和维护患者的健康。
• [EN] MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV<br/>[FR] INHIBITEURS MACROCYCLIQUES DE LA SÉRINE PROTÉASE MACROCYCLIQUE UTILES CONTRE LES INFECTIONS VIRALES, EN PARTICULIER LE VIRUS DE L’HÉPATITE C
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2011017389A1

  公开（公告）日：2011-02-10

  Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula (Ia) or (Ib), pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

  本文提供了大环丝氨酸蛋白酶抑制剂化合物，例如，化学式（Ia）或（Ib）所示的化合物，包括这些化合物的药物组合物，以及其制备方法。还提供了它们用于治疗宿主中HCV感染的方法。
• MACROCYCLIC SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING HCV INFECTIONS
  申请人：PARSY Christophe Claude

  公开号：US20120207703A1

  公开（公告）日：2012-08-16

  Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, and pharmaceutical compositions and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

  本文提供了大环丝氨酸蛋白酶抑制剂化合物，例如，Formula I的化合物，以及其制备的药物组合物和过程。还提供了它们用于治疗宿主中HCV感染的方法。